Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lapatinib + pemetrexed
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lapatinib + pemetrexed is a combination therapy consisting of two small molecule drugs used in oncology. Lapatinib is a dual tyrosine kinase inhibitor that targets the intracellular domains of both epidermal growth factor receptor (EGFR/ERBB1) and human epidermal growth factor receptor 2 (HER2/ERBB2), thereby inhibiting tumor cell proliferation driven by these pathways. Pemetrexed is an antifolate antineoplastic agent that disrupts folate-dependent metabolic processes essential for cell replication by inhibiting multiple enzymes involved in nucleotide synthesis, including thymidylate synthase. This combination has been studied primarily as a second-line treatment for advanced or metastatic non-small-cell lung cancer (NSCLC), with evidence suggesting it is well tolerated and has similar efficacy to pemetrexed monotherapy[1][3][2]. Lapatinib was developed by GlaxoSmithKline, while pemetrexed was developed by Eli Lilly.
- Brand names
- Tykerb + AlimtaTykerb + Pemfexy
02
Targets
DHFR (Dihydrofolate reductase)EGFR (Epidermal growth factor receptor)GART (GAR transformylase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on lapatinib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lapatinib + pemetrexed.